Summary

  • PDS Biotechnology’s 31 August amendment covers a note issued with US$6 million of original principal. It becomes effective only after the 14 September instalment is paid in full.
  • ATM cash first covers the next instalment and interest. Once that amount is satisfied, PDS may retain 40% of excess net proceeds while 60% goes to the holder for later instalments.
  • Net cash from an equity or equity-linked financing outside the ATM follows a different path: 100% becomes a deemed redemption payable to the holder within five business days.
  • The amendment extends a Nasdaq-deficiency cure period from 75 to 180 days, but does not remove the underlying special-amortisation mechanism or waive holder rights.
  • PDS reported US$5.6 million of cash at 30 June and US$7.2 million of six-month operating cash use. Gross financing capacity is therefore less informative than cash retained after the note waterfall.

One issuer, two routes for new equity cash

A company can announce an equity financing in one number. Its creditors can make that number travel through several accounts before it reaches operations.

That is the economic detail inside PDS Biotechnology’s Form 8-K filed on 4 September. PDS and YA II PN amended a promissory note that was issued on 15 June with original principal of US$6 million. The revision divides future equity proceeds into two categories: cash raised through the existing at-the-market programme and cash raised through a bona fide equity or equity-linked financing outside that programme.

The amendment does not yet supply an unconditional closing receipt. Its effectiveness clause requires executed delivery and payment in full of the instalment due on 14 September. Until that condition is met, signature and effectiveness remain separate states.

If it takes effect, the source of the next equity dollar will determine its first destination.

ATM proceeds service the nearest instalment first

Under the revised ATM clause, PDS must send the holder a weekly notice whenever it received ATM net proceeds during the prior week. The applicable amount must be paid within one business day after the notice.

The allocation happens in sequence. ATM net proceeds first cover the principal amount due on the next instalment date, including any permitted increase through the note’s acceleration provision, plus accrued interest. Only after that near-term amount has been paid does the 40/60 formula apply. PDS may retain 40% of the excess; 60% must go to the holder and is applied to later monthly principal and interest in inverse chronological order.

It would therefore be wrong to say that PDS keeps 40 cents of every ATM dollar. The creditor takes the first dollars needed for the next instalment. The split begins only above that threshold.

The distinction also makes an ATM’s advertised capacity a poor measure of operating liquidity. PDS’s June-quarter report describes a programme permitting up to US$50 million of common-stock sales. By 30 June, however, the company had sold only 106,153 shares under that June programme for about US$100,000 of net proceeds. Capacity was not cash, and cash sold into the market was not automatically cash free for research.

A non-ATM raise has the steeper waterfall

The new section for outside financing is simpler and more restrictive. If PDS receives net cash from a bona fide equity or equity-linked capital raise outside the ATM, receipt itself is treated as delivery of a redemption notice. The redemption amount equals 100% of those net proceeds and must be paid to the holder within five business days.

The holder applies the money first to accrued and unpaid interest and then to principal. A partial redemption reduces future monthly instalments in reverse chronological order.

This is not a claim that the creditor can take more than the remaining obligation, or that a sufficiently large financing must leave PDS with nothing. The public filings do not state the principal outstanding after the September payment. The accurate reading is narrower: while the note remains outstanding, the contract gives qualifying non-ATM net proceeds a creditor destination before they can be treated as general operating cash.

That changes the meaning of an equity-raise headline. Gross proceeds are reduced by offering costs to reach net proceeds. The note then allocates those net proceeds. Only the residual is the amount that can extend the company’s operating choices.

The liquidity baseline is dated, but it is not abstract

At 30 June, PDS reported US$5.596 million of cash and cash equivalents. It had used US$7.164 million of cash in operations during the first six months of 2026 and recorded a US$17.100 million net loss. The historical operating-cash use averaged roughly US$1.19 million per month, though that arithmetic is not a runway forecast.

The company concluded that substantial doubt existed about its ability to continue as a going concern for at least 12 months from issuance of the statements. It said future funding could come from equity, debt, collaborations, strategic alliances, licensing or government programmes, and warned that unavailable financing could force it to delay, reduce or terminate development work.

Those disclosures explain why the routing of equity cash matters. PDS had not generated product revenue. It needs capital to convert clinical and regulatory work into a later commercial possibility. A dollar used to retire debt can improve the capital structure, but it cannot simultaneously pay a laboratory, trial site or supplier.

The note itself was issued for US$6 million of principal, carried 10% ordinary interest and produced US$5.76 million of gross proceeds, according to the 10-Q. The original note allows the holder, from 15 September, to accelerate up to US$1.6 million of aggregate principal amortisation, with no more than US$700,000 in one month and 30 days’ notice. The amendment leaves that control surface in place.

More time on Nasdaq is not a waiver

One term moves in PDS’s favour. A Nasdaq listing-deficiency notice originally became a special amortisation event if it remained uncured after 75 days. The amendment extends that period to 180 days.

The longer clock matters because the original mechanism could replace an ordinary instalment with as much as US$2 million of principal, plus a 3% payment premium and interest, while the special event continued. Extending the cure period makes that particular trigger less immediate. It does not abolish it.

Nor should the amendment’s strict-compliance language be converted into an allegation. YA II did not waive or agree to forbear from any default, and the agreement preserves its existing rights. Reservation of a remedy is not evidence that the remedy has become exercisable. The filing does not say PDS was in default.

The number to watch is retained cash

PDS now has three related but non-interchangeable ledgers. The equity ledger records shares sold and dilution. The debt ledger records interest, principal, instalments and redemptions. The operating ledger records the cash left to fund development.

The amendment joins the first two more tightly. Selling equity may retire debt, but the financing headline will overstate immediate operating liquidity unless it also shows which route the proceeds used, how much principal and interest remained, and how much cash PDS retained.

That is neither proof that a financing will fail nor an argument that debt repayment destroys value. It is a demand for the right receipt. In a clinical-stage company, capital does not become runway when a term sheet is signed or shares are sold. It becomes runway only after costs and contractual waterfalls have been paid.

Sources